Leishmania tarentolae expressing CXCL‐10 as an efficient immunotherapy approach against Leishmania major‐infected BALB/c mice

• DOI: 10.1111/pim.12461
• Publication Date: 2017-08-18T14:52:38Z
• Authors: H. Montakhab‐Yeganeh; Z. Abdossamadi; F. Zahedifard; Y. Taslimi; A. Badirzadeh; N. Saljoughian; T. Taheri; M. Taghikhani; S. Rafati
• Keywords: 0301 basic medicine; Mice, Inbred BALB C; Arginase; Interleukin-6; Leishmaniasis, Cutaneous; Genetic Therapy; Th1 Cells; Nitric Oxide; Interleukin-10; 3. Good health; Chemokine CXCL10; Interferon-gamma; Mice; 03 medical and health sciences; Animals; Immunotherapy; Interleukin-4; Leishmania major

Recent findings have demonstrated the suitability of interferon-gamma-induced protein 10 (IP-10) or CXCL-10 as an immunotherapy tool in treatment leishmaniasis. This chemokine can overcome Leishmania (L.) infection through inducing nitric oxide (NO) production for parasite elimination. study was undertaken to investigate therapeutic effects recombinant tarentolae expressing and expression vector encoding (pcDNA-CXCL-10-EGFP) a model BALB/c mice susceptible by major. The outcome intervention examined at 3 weeks post-treatment evaluating parameters burden (PB), arginase activity, NO various cytokines such IFN-γ, IL-4, IL-6 IL-10. results shown that despite efficacy gene therapy, live therapy strategy using L. more effective terms decreasing PB. Nitric increased, especially approaches. Arginase activity also decreased all regimens, which demonstrates potency treatment. overall cytokine shifted favour Th1 responses treated mice. Altogether, represents promising improve cutaneous